Literature DB >> 8077196

Aggregation of the intracellular domain of the type 1 tumor necrosis factor receptor defined by the two-hybrid system.

H Y Song1, J D Dunbar, D B Donner.   

Abstract

The yeast-based two hybrid system has been used to determine whether oligomerization of the intracellular domain of the 55-kDa type 1 tumor necrosis factor (TNF) receptor may occur during TNF action. This assay depends upon reconstitution of the function of the GAL4 transcriptional activator through interaction of a protein fused to the GAL4 DNA binding domain with a protein fused to the transcriptional activation domain of GAL4. Fusion of the type 1 TNF receptor intracellular domain with the DNA binding domain and the transactivation domain of GAL4 led to activation of the lacZ indicator gene, demonstrating interaction of the receptor intracellular domain with itself. A HeLa cell cDNA library was searched for proteins that interact with the intracellular domain of the type 1 TNF receptor. A protein corresponding to amino acids 329-426 in the type 1 TNF receptor intracellular domain was identified by this screen. The aggregation domain was further defined by testing the ability of deletion mutants of the type 1 TNF receptor intracellular region to interact with the complete intracellular domain. These experiments map the aggregation domain to a sequence of amino acids previously shown to be responsible for mediating TNF-induced cytotoxicity. These results suggest that aggregation of type 1 TNF receptor intracellular domains may be important in TNF signal transduction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077196

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  PLAIDD, a type II death domain protein that interacts with p75 neurotrophin receptor.

Authors:  Harald Frankowski; Susana Castro-Obregon; Gabriel del Rio; Rammohan V Rao; Dale E Bredesen
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

Review 2.  Looking beneath the surface: the cell death pathway of Fas/APO-1 (CD95).

Authors:  B Z Stanger
Journal:  Mol Med       Date:  1996-01       Impact factor: 6.354

3.  The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure.

Authors:  M Leist; F Gantner; G Künstle; I Bohlinger; G Tiegs; H Bluethmann; A Wendel
Journal:  Mol Med       Date:  1996-01       Impact factor: 6.354

4.  The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation.

Authors:  H Y Song; M Rothe; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

5.  HTLV-I Tax self-association in optimal trans-activation function.

Authors:  D Y Jin; K T Jeang
Journal:  Nucleic Acids Res       Date:  1997-01-15       Impact factor: 16.971

6.  Tumor necrosis factor receptor 1 is an ATPase regulated by silencer of death domain.

Authors:  Kiyoshi Miki; Edward M Eddy
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

7.  Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor.

Authors:  C M Chen; L R You; L H Hwang; Y H Lee
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

8.  The yeast nucleoporin Nup53p specifically interacts with Nic96p and is directly involved in nuclear protein import.

Authors:  B Fahrenkrog; W Hübner; A Mandinova; N Panté; W Keller; U Aebi
Journal:  Mol Biol Cell       Date:  2000-11       Impact factor: 4.138

Review 9.  [Apoptosis--what is it? Significance in coronary heart disease and myocardial infarct].

Authors:  J Holtz; H Heinrich
Journal:  Herz       Date:  1999-05       Impact factor: 1.443

10.  Sall2 is a novel p75NTR-interacting protein that links NGF signalling to cell cycle progression and neurite outgrowth.

Authors:  Roxana Pincheira; Melinda Baerwald; James D Dunbar; David B Donner
Journal:  EMBO J       Date:  2009-01-08       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.